Telotristat Ethyl

Neuroendocrine Tumors

Andrew Hendifar, MDSmall moleculeDormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 73/ 100

Competitive context

62 Active assets in the Neuroendocrine Tumors cohort.

Asset / Sponsor	Phase	Rating
Irinotecan First Affiliated Hospital Xi'an Jiaotong University	Phase 4	BB
Bms-907351 Fox Chase Cancer Center	Phase 3	BB
Eloxatin ITM Solucin GmbH	Phase 3	BB
FLUOROURACILUM ITM Solucin GmbH	Phase 3	BB
Pasireotide RECORDATI GROUP	Phase 4	BB

View all 50 →

Same molecule, other indications

Telotristat Ethyl is also rated in:

pancreatic adenocarcinomaDormant

B

Indicative ·

57 / 100

malignant pancreatic neoplasmDormant

B

Indicative ·

57 / 100

carcinoid syndromeDormant

CC

Indicative ·

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.